Galapagos develops therapies with proprietary, novel modes-of-action. Filgotinib, Galapagos' most advanced novel mode-of-action program, was discovered using the Company's proprietary target discovery technology, and then further developed by us through to Phase 2B. Galapagos is progressing multiple programs in inflammation, cystic fibrosis, metabolic diseases, fibrosis, and other disease areas.
We have a strong investor base, with a long term commitment to the biotech industry. Whether you are a current investor in Galapagos or are evaluating Galapagos as a potential investment opportunity, we welcome you to contact us should you have any additional questions after reviewing our website.
For all your investor relations questions and to request receipt of press releases, annual reports, and other materials:
Head of Corporate Communications & Investor Relations
Mobile: +31 622916240